BioTissue Holdings has completed the sale of its non-ocular Surgical and Wound Care business to BioStem Technologies, a deal that shifts BioTissue toward a tighter strategic focus on eye-care innovation while expanding BioStem’s footprint in placental-derived products for advanced wound care.
As part of the agreement, BioStem acquired exclusive rights to BioTissue’s Neox and Clarix product lines. BioTissue’s Surgical sales team and key support staff will transition to BioStem’s commercial organization, while BioTissue will continue manufacturing the products for BioStem under the new arrangement.
BioTissue said the divestiture allows it to concentrate its commercial strategy and resources on interventional therapies for acute and chronic ocular surface conditions. The company’s ocular portfolio includes Prokera, CAM360 AmnioGraft, AmnioGraft, and AmnioGuard, and BioTissue said it will prioritize product innovation, professional education, and customer support for eye-care providers.
BioStem framed the acquisition as a complementary addition to its existing business, citing the opportunity to increase focus and investment in commercial execution across surgical and wound care applications.
BioTissue, which specializes in cryopreserved amniotic membrane products, said its platform is supported by broad clinical usage and a substantial body of published research. BioStem, meanwhile, said it develops and manufactures perinatal tissue allografts using its BioRetain processing method and operates an FDA-registered, AATB-accredited facility in Pompano Beach, Florida.
KEY QUOTES:
“Since our founding, our mission has been to transform patient outcomes through regenerative therapies. This divestiture is a catalyst for our next chapter, one focused squarely on eye care innovation. With a streamlined portfolio and dedicated resources, we are poised to deliver breakthrough solutions and support to our ocular customers and their patients. At the same time, BioStem’s commitment to advancing surgical and wound care applications ensures our technology continues to make a profound impact on physicians and patients across specialties. We are grateful to the Surgical team for their contributions and are excited to see them thrive with BioStem.”
Ted Davis, President and CEO, BioTissue
“With its world-class commercial team and differentiated portfolio of products, BioTissue has established a solid foundation of business in the surgical and wound care sectors. BioTissue’s strengths are a natural complement to our existing business and we see a tremendous opportunity to provide focus and investment in commercial execution, driving continued growth and improving patient lives and outcomes.”
Jason Matuszewski, CEO and Chairman, BioStem
